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Abstract 
 
Background 
Elderly patients are more likely to have oestrogen receptor positive cancers that 
can be treated without surgery with Primary Endocrine Therapy (PET).  Few 
studies have sought to identify predictors of failure of PET and so the aim of this 
study was to evaluate treatment failures in elderly breast cancer patients treated 
with PET and to determine predictors of failure.  
 
Methods 
A retrospective observational study was performed on consecutive patients with 
ER positive early stage breast cancer treated with PET between 2005 and 2015 
in the three breast units in the north east of England.  The primary outcome 
measure was treatment failure and secondary outcome measure was disease 
progression.  
 
Results 
488 patients were included with mean follow up 31 months (SD 23).  Overall, 
206 patients were still alive with their disease controlled at the end of follow up, 
219 had died with their disease controlled and 63 (12%) experienced treatment 
failure.  Younger age [SHR 0.96 (95% CI 0.94 to 0.99) p 0.013], larger tumours 
[SHR 1.03 (1.01 to 1.06) p 0.015], grade 3 cancers [SHR 3.58 (1.93 to 6.63) 
p<0.001] and axillary lymph node metastases [SHR 1.93 (1.06 to 3.52) p 0.030] 
were all independent predictors of treatment failure. Disease progression was 
reported in 86 (17.6%) of patients. 
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Conclusions 
This is the largest retrospective series evaluating PET treatment failure.  Clear 
predictors of failure have been identified, which can be used to facilitate 
treatment decision-making. These results support previous analyses, further 
validating our results.    
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INTRODUCTION 
Frailty and the burden of co-morbid disease increase with advancing age[1], as 
does the incidence of breast cancer[2].  Whilst surgery is the standard initial 
treatment of choice for early breast cancer[3], some elderly and frail patients 
with oestrogen receptor (ER) positive cancers  who are considered too unfit for 
general anaesthesia, may be given primary endocrine therapy (PET)[4,5].   PET 
has been shown to be effective in treating breast cancer[6].  
 
PET use has become widespread. In 2012 a UK-based questionnaire study 
reported that 93% of surgeons advocated the use of PET in early operable breast 
cancer in the elderly[7].  Whilst PET provides relatively good local control in the 
short term (2-3 years), it has been found to be inferior to surgery long-term.  
This was shown in a Cochrane meta-analysis that showed no difference in overall 
survival between PET and surgery, but an inferiority of PET in local disease 
control[8]. However, all but one study included were unselected for oestrogen 
receptor (ER) status, and all used Tamoxifen which has now largely been 
superseded by Aromatase inhibitors (AIs)[9].  
 
The International Society of Geriatric Oncology (SIOG) advise that PET may be 
considered in patients with a short life expectancy (<2 years) or unfit for 
surgery[10]. Frequently, clinician’s decision making in allocating PET is 
subjective, made in a busy time-pressured outpatient clinic, with little 
objectivity. NHS time- targets may also influence clinician’s decision making[11], 
as formal anaesthetic or geriatric opinions can take time.  
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Treatment failure on PET is potentially catastrophic for the patient. As such, 
patient selection is key.   Difficulties in patient selection are compounded by an 
increasing life expectancy, with patients with multiple co-morbidities able to live 
longer due to improvements in geriatric and medical care[12-14].   Few studies 
have directly sought to analyse failure of PET.   The aim of this study was to 
determine the failure rate of PET in the North East of England, and to identify 
predictors of failure.   
 
 
METHODS 
An observational study was performed on patients with ER positive early breast 
cancer treated with PET between January 2005 and December 2015.  Data 
collection was performed retrospectively and subjects were identified from the 
three North East of England breast-screening units.   Local breast cancer multi-
disciplinary team databases were used to select patients.  Patients were excluded 
if they had inoperable or metastatic disease at presentation, or if endocrine 
therapy was given as neo-adjuvant treatment to downstage the tumour prior to 
surgery.  
 
Tumour characteristics 
Pathological information was based on needle-core biopsies on first 
presentation.  Strength of ER status was determined by the histochemical 
‘quickscore’ (value out of eight)[15]. HER-2 positivity was defined by 
immunohistochemistry or fluorescent in-situ hybridization (FISH) in borderline 
cases[16]. The grade of the tumour was catergorised 1-3 by the modified Scarf-
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Bloom-Richardson (SBR) criteria[17].  Lymph node involvement was recorded 
either from histology or cytology, and in some cases based purely on ultrasound 
appearances if a tissue-sample was not acquired. Tumour size was based on the 
maximum dimensions from ultrasound.  
 
Treatment decisions and patient characteristics 
Patients were seen for diagnosis and treatment planning in the outpatient clinic, 
with support from the local Multidisciplinary team (MDT). Case notes and 
outpatient clinic letters were reviewed to determine the first choice of endocrine 
agent.  Data on patient co-morbid disease, cognition and social circumstances 
was also collected.   Consultation by geriatricians or anaesthetists was recorded.  
The use of predictive indexes which facilitate decision making were recorded, as 
was any additional information on other surgeries unrelated to their breast 
cancer following diagnosis.  
 
Follow up  
Length of follow up was determined by case note review. The date of diagnosis 
was taken from when the diagnosing histology was made available. Patients 
were ultimately followed up until they died, or were still under follow up at the 
censor point (December 2015). Cause of death was either determined from the 
case notes or from the patient’s general practitioner.  
 
Outcome variables 
The primary outcome measure was treatment failure. This was defined as 
patients either dying with uncontrolled local disease; patients dying of 
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metastatic breast cancer (where there was only local disease on presentation), 
or patients requiring surgery or radiotherapy to control local progression. Time 
to failure was recorded either from diagnosis to death, or diagnosis to surgery or 
radiotherapy.  Treatment was considered a success if the patient died of causes 
unrelated to their breast cancer and their disease was under control at that 
point, or if they were still alive at the time of censoring with their disease 
controlled.  
The secondary outcome measure was disease progression. This was defined as 
an increase in size of tumour whilst on PET. Time to progression was recorded 
from diagnosis to when the tumour clinically or radiologically increased in size.  
 
Statistical analysis 
Patients still alive without treatment failure were censored at end of follow-up at 
end of December 2015.  Characteristics in the three groups (treatment failures, 
patient who died with controlled disease and patients still alive with controlled 
disease) were compared using the Kruskal Wallis test, Chi-square test or Fisher’s 
exact test, as appropriate. Where patients had bilateral disease, tumour size and 
characteristics were summarised using data from the largest or most advanced 
tumour.  
The cumulative risk of death with controlled disease and risk of treatment failure 
was calculated with the alternate outcome treated as a competing risk. 
Competing risks regression models were used to identify factors associated with 
dying with controlled disease and with treatment failure.  Results are presented 
as sub-hazard ratios (SHR) with 95% confidence intervals (CI).  
Analysis was carried out using STATA 14IC.  
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RESULTS 
Data were included from 488 patients who were followed for a total of 1271 
person years. Among all patients the mean follow up was 31.3 (standard 
deviation = 23.0) months with a median of 28 months (Interquartile range = 5 to 
41). Among 232 patients who died mean follow up was 27.4 (24.0) months and 
median 21 (10 to 36 months). The remaining 255 patients were alive at the end 
of December 2015 by which time they had provided a mean follow up of 35.5 
(21.1) months and median of 32 (21 to 45) months.  465 (95.2%) patients were 
started on Letrozole as their initial therapy, Tamoxifen in 18 (3.7%) and the 
remaining 5 (1.1%) either Anastrazole or Exemestane.   
 
Patient characteritistics 
Characteristics of included patients are summarised in table 1. Overall, 206 
patients were still alive with their disease controlled at the end of follow up, 219 
had died with their disease controlled and 63 experienced treatment failure. 
Patients who died with their disease controlled were older at diagnosis 
(p=0.014) and had more comorbidities (p=0.010) than other patients. Median 
tumour size at diagnosis was 30mm in those who failed treatment, compared to 
25mm in others (p=0.038). Tumours in patients who failed treatment were also 
more likely to be TPM grade 3 (p<0.001) and almost half of the patients had 
lymph node involvement compared to <20% in patients without treatment 
failure (p<0.001). 
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Risk of treatment failure  
The cumulative risks of death with disease controlled and of treatment failure 
are summarised in Table 2 and Figure 1. By 12 months 15.6% (12.5 to 19.0) 
patients had died without treatment failure, rising to 51.5% (45.8 to 56.9) at 60 
months and 65.1% (57.8 to 71.4). By the 96 months 20.8% (15.8 to 26.2) of 
patients had experienced a treatment failure.  
 
Predictors of treatment outcome  
The associations between patient and disease characteristics and both death 
with disease control and hazard of treatment failure were explored with the 
results summarised in table 3.  Increasing age, more comorbidities, impaired 
mobility, cognitive impairment and nursing home residency were all associated 
with dying with disease controlled. Patients who were older, with more 
comorbidities and less independent were more likely to die with their disease 
controlled.  
On the other hand, tumour size, TPM grade, axilla involvement and vascular 
involvement were the only factors associated with treatment failure.  Patients 
with large and more advanced disease are more likely to experience treatment 
failure.  
Next, multivariate regression analysis was used to identify all independent 
predictors of dying with disease controlled and of treatment failure with the 
results summarised in table 4. Increasing age and more comorbidities were both 
independent predictors of dying with disease controlled. The likelihood of dying 
with controlled disease increased by 2% for every year increase in age 
(SHR=1.02, 1.00 to 1.04).  Younger age (SHR=0.96, 0.94 to 0.99), increasing TPM 
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grade (SHR=3.58, 1,93 to 6.63) and axilla involvement were also associated with 
treatment failure, with patients with axilla involvement almost twice as likely to 
experience treatment failure (SHR=1.93, 1.06 to 3.52). 
 
Details of treatment failures are summarised in table 5. Of the 63 patients who 
experienced failure, 32 (50.8%) died with uncontrolled disease and 22 (34,9%) 
from breast cancer. The median time to first failure was 28 (14 to 41) months.  
 
Disease progression was reported in 86 (17.6%) of patients. Of those 66 (80.5%) 
continued on PET, usually with a change of agent. Treatment failure was 
observed in 51 (59.5%) who had progressed, 18 (20.9%) had died without 
failure and the remaining 17 (19.8%) were still alive without failure at end of 
December 2015.  
 
Treatment planning  
270 (55.3%) patients were offered surgery in the first instance. 
46 (9.4%) patients were referred for an anaesthetic assessment as part of their 
treatment planning. 5 (1%) patients had a geriatric assessment. 17 (3.4%) had a 
documented frailty or risk score performed by the surgeon. 14 patients had 
surgery following their diagnosis on unrelated problems requiring general 
anaesthesia, of which 3 were for hip or knee arthroplasty.  
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DISCUSSION 
Advanced age and a higher burden of co-morbid disease are associated with 
dying with controlled disease. Younger patients, who tend to live longer, are 
more likely to experience treatment failure. Younger patients with higher 
histological grade, larger tumours and axillary lymph node metastases are most 
at risk of treatment failure.   
 
This observational study provides the largest retrospective patient series in the 
literature investigating treatment failure of PET in elderly women.  Previous 
failure rates of PET that have been published range from 12% to 84%[18-32].  
Many of these included patients unselected for ER status however, and used 
Tamoxifen as the primary treatment.   Letrozole was the predominant drug of 
choice in over 95% of our cohort. Whilst the superiority of Aromatase Inhibitors 
(AIs) has been shown in the adjuvant[33], neo-adjuvant[34] and palliative 
settings[35] in post-menopausal women, no randomised trial exists for 
comparison for use as a primary endocrine agent. However, with our 
comparatively low rate of treatment failure (12.9%), this suggests an advantage 
of Letrozole over Tamoxifen for use in PET.   Our low rates of failure also suggest 
good clinical acumen, despite the lack of additional specialist input.  
 
Randomised trials comparing surgery with PET identified the superiority of 
surgery in controlling local disease long-term, which suggested that PET could be 
given to good effect in the short-term, but those living longer were more at risk 
of disease progression. However, few trials have sought to determine other 
factors associated with PET failure. Most recently, Layfield et al [36] reported 
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that high-grade disease and axillary lymph node involvement independently 
predicted early failure.  Tumour size has also been found to be an independent 
predictor[23], although this was in a cohort unselected for ER status. Our 
findings, in a larger cohort, not only validate these previous results but also 
found that histological evidence of vascular invasion (SHR 2.48 CI [1.15 to 5.34] 
p=0.020) was significantly associated with treatment failure in univariable 
regression analysis.  An early study associated HER-2 positivity with treatment 
failure[37], however our results failed to show this, likely due to the low 
numbers in our cohort with positive HER-2 status.  
 
The International Society of Geriatric Oncology (SIOG) and European Society of 
Breast Cancer Specialists (EUSOMA)[10] recommend that PET should only be 
offered to patients with a “short estimated life expectancy (less than 2 to 3 
years), who are considered unfit for surgery or who refuse surgery”.  The mean 
time to failure in our cohort was about 30 months, with the mean time to 
requiring radiotherapy and surgery 26.5 and 29.7 months respectively.  On one 
hand, this would support such a time frame. However, the probability of a 
patient at three years of dying of a non-breast related cause with controlled local 
disease is 39%, with a 10% failure probability. This means that approximately 
half of patients would still be alive with controlled local disease at this point. 
Then, looking further ahead at five years, just fewer than 35% of patients would 
be predicted to still be alive with disease control. One could therefore argue that 
PET does have a role longer term contrary to current guidance.  Ultimately in 
clinical practice patient choice plays a crucial role.  
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As part of the Bridging the Age Gap in Breast Cancer Trial[38], Morgan et al 
reported that increasing age, higher levels of comorbidity, large tumour size and 
dependence in one or more ADL categories were strongly associated with non-
surgical treatment. We found that those older, more co-morbid patients were 
more likely to die of non-breast cancer related causes with their disease 
controlled and thus have successful treatment with PET. Interestingly larger 
tumour size independently predicted treatment failure in our cohort and so 
taking into consideration initial results by Morgan et al, if a patient is fit enough 
for surgery then they should be encouraged to have it.  
 
Despite evidence that clinical judgment alone is an inaccurate measure of life 
expectancy[39,40], we could not demonstrate a difference in failure between 
those who had additional non-surgical clinical input and those whose decisions 
were made by the surgeon alone.  This is because few patients had allied-health 
reviews.   The low uptake of geriatric and anaesthetic involvement may reflect 
local service challenges, and highlight that decision making for PET is largely 
subjective.  SIOG advises geriatric involvement in all elderly cancer treatment 
decision-making processes, but none of the local units involved in this study 
within the time frame for recruitment had routine access to specialist surgical 
and oncological liason geriatricians.  This may help explain why 14 patients had 
surgery for non-breast related problems following their breast cancer diagnosis, 
including 3 joint replacement operations.  
 
Morgan et al[38] acknowledged the difficulty in recruitment in trials involving 
the elderly[41].  Conducting a retrospective observational study such as this 
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avoids such issues. However, there are limitations.  The majority of the 
information gained was reliant on case records, in particular treatment 
decisions, documentation of co-morbidities, living arrangements and mobility. 
There was a large degree of heterogeneity in how comprehensive clinic letters 
were. To account for this, nursing notes, routinely filed in the case records were 
also examined. Surveillance of tumours was also variable. Some patients would 
purely have clinical follow up where clinical examination would assess for 
disease control, whereas others would use mammography and ultrasound.  Much 
of these problems are the result of a retrospective study design, and involving 
breast units from three independent NHS trusts.   There is a positive however of 
a multi-institution study as it reflects wider practice and natural variations 
between units. This in turn makes the results more generalisable to other breast 
units.  
 
This series has identified key factors associated with treatment failure on PET. 
Younger patients, with larger high-grade tumours and axillary node metastases 
would benefit from surgery over primary endocrine therapy.  Patients with 
limited life expectancy, can be treated with PET as it likely they will die from 
non-breast cancer related causes.  Treatment decision making in elderly patients 
in routine clinical practice is a challenge, particularly as not all patients fall into 
two distinct groups as described above.  There is evidence from this series that 
some patients living beyond three years can maintain disease control longer-
term, and as such adds to the difficulty in accurately advising patients as to the 
most appropriate treatment.  Surgery has been shown to be safe with regional 
anaesthesia[42], allowing increasingly frail patients greater access to surgery, 
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and as such should be the standard of care for operable breast cancer. PET with 
AIs in post-menopausal women may be a viable long-term alternative in the right 
circumstance and in the absence of failure risk factors.  A specific prognostic 
index to identify the likelihood of treatment failure would give more objectivity 
in treatment planning, allowing the clinician to counsel the patient appropriately. 
However, no such model is yet widely available.   
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Tables and Figures 
Table 1. Patient and disease characteristics by outcome 
 All Alive with 
disease 
controlled 
Died with 
disease 
controlled 
Failed 
treatment 
p-value 
Total 488 206 219 63  
Age at diagnosis, median (IQR) 83 (78.5 to 88) 82.5 (78 to 87) 85 (79 to 90) 83 (77 to 87) 0.014 
Tumour size, median (IQR),  
(missing: n=6) 
25 ( 20 to 35) 25 (18 to 35) 25 (20 to 34.5) 30 (20 to 45) 0.038 
Bilateral disease, n (%) 22 (4.5) 12 (5.8) 8 (3.7) 2 (3.2) 0.481 
HER2 Pos, n (%) 
(missing: n=83) 
32 (7.9) 14 (8.1) 11 (6.1) 7 (13.5 0.218 
TPM grade, n(%) 
(missing: n=19) 
    <0.001 
   1 49 (10.5) 25 (12.8) 21 (9.9) 3 (4.9)  
   2 361 (77.0) 153 (78.5) 169 (79.3) 39 (63.9)  
   3 59 (12.6) 17 (8.7) 23 (10.8) 19 (31.2)  
Strength ER positivity, n(%) 
(missing: n=5) 
    0.001 
   Weak (3-4) 5 (1.0) 1(0.5) 3(1.4) 1(1.6)  
   Moderate (5-6) 12 (2.5) 1(0.5) 5(2.3) 6(9.5)  
   Strong (7-8) 466(95.5) 202(98.0) 209(95.4) 55(87.3)  
Avilla involvement, n(%) 
(missing: n=3) 
114 (23.5) 38 (18.6) 45 (20.6) 31 (49.2) <0.001 
Vascular invasion, n(%) 
(missing: n=16) 
32 (6.8) 10 (5.1) 14 (6.5) 8 (13.6) 0.072 
Histological subtype 
(missing: n=11) 
    0.556 
   IDC 375 (78.6) 159 (79.5) 166(77.2) 50 (80.7)  
   ILC 70 (14.7) 30 (15.0) 30 (14.0) 10 (16.1)  
   Other 32(6.7) 11 (5.5) 19 (8.8) 2(3.2)  
Prev unrelated Breast cancer, n 
(%) 
(missing: n=5) 
31 (6.4) 11 (5.5) 17 (7.8) 3 (4.8) 0.634 
Co-morbiditiesa, n(%) 
 (missing: n=5) 
1 (1 to 2) 1 (0 to 2) 2 (1 to 2) 1 (0 to 2) 0.010 
   0 120 (24.6) 56 (27.2) 43 (19.6) 21 (33.3) 0.058 
   1 to 2 276 (56.6) 118 (57.3) 125 (57.1) 33 (52.4)  
   3 or more 92 (18.9) 32 (15.5) 51 (23.3) 9 (14.3)  
Impaired mobilityb, n (%) 
(missing: n=6) 
350 (71.7) 133 (64.6) 173 (79.0) 44 (69.8) 0.004 
Cognitive impairment, n (%) 
(missing: n=3) 
134 (27.6) 48 (23.7) 74 (33.8) 12 (19.1) 0.019 
Carers at home, n (%) 
(missing: n=3) 
129 (26.6) 42 (20.7) 67 (30.6) 20 (31.8) 0.039 
Nursing home resident, n (%) 
(missing: n=3) 
136 (28.0) 45 (22.2) 78 (35.6) 13 (20.6) 0.004 
 
aCalculated as number of comorbidities from the following list: IHD, cardiac 
failure, stroke/neurological disease, significant pulmonary disease and diabetes 
bDefined as using a walking aid or wheelchair 
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Figure 1: Probability of death with controlled disease and of treatment 
failure. 
 
 
 
Table 2: Probability of death with controlled disease and of treatment failure. 
 
Time Cumulative percentage dying 
with disease controlled, 
% (95% CI) 
Cumulative percentage 
with treatment failure, 
% (95% CI) 
12 months 15.6 (12.5 to 19.0) 2.5 (1.4 to 4.2) 
24 months 29.0 (24.9 to 33.2) 6.2 (4.2 to 8.6) 
36 months 39.0 (34.3 to 43.8) 10.8 (8.0 to 14.1) 
48 months 46.7 (40.5 to 50.8) 13.1 (9.8 to 16.8) 
60 months 51.5 (45.8 to 56.9) 16.2 (12.4 to 20.7) 
72 months 59.5 (53.0 to 65.5) 19.7 (15.1 to 24.8) 
84 months 61.5 (54.7 to 67.5) 20.8 (15.8 to 26.2) 
96 months 65.1 (57.8 to 71.4) 20.8 (15.8 to 26.2) 
 
Table 3: Results of univariable competing risks regression analysis 
 Event = Death with disease controlled Event =Treatment failure 
 SHR 95% CI p-value SHR 95% CI p-value 
Age 1.02 1.01 to 1.04 0.010 0.98 0.97 to 1.00 0.076 
Tumour size 1.00 0.99 to 1.01 0.394 1.03 1.02 to 1.05 <0.001 
Bilateral disease 0.79 0.40 to 1.57 0.497 0.70 0.18 to 2.69 0.606 
HER2 Pos 0.84 0.43 to 1.66 0.624 2.22 1.01 to 4.85 0.047 
TPM grade 0.95 0.70 to 1.29 0.754 3.37 1.96 to 5.67 <0.001 
Axilla involvement 0.81 0.58 to 1.13 0.216 3.69 2.27 to 6.00 <0.001 
Vascular involvement 0.94  0.56 to 1.56 0.806 2.48 1.15 to 5.34 0.020 
Strength ER positivity 0.91 0.76 to1.09 0.309 0.75 0.56 to 1.01 0.059 
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ILC 1.03 0.69 to 1.54 0.885 1,01 0.57 to 2.13 0.781 
Other histological subtype 1.35 0.87 to 2.10 0181 0.41 0.10 to 1.60 0.199 
Prev unrelated Breast cancer 1.08 0.71 to 1.66 0.715 0.63 0.20 to 2.00 0.429 
Co-morbidities*       
   0 1  0.015 1  0.154 
   1 to 2 1.32 0.93 to 1.86  0.65 0.38 to 1.11  
   3 or more 1.80 1.21 to 2.70  0.52 0.24 to 1.11  
Impaired mobility 1.48 1.07 to 2.03 0.017 0.80 0.47 to 1.37 0.421 
Cognitive impairment 1.52 1.16 to 1.99 0.002 0.59 0.32 to 1.12 0.106 
Carers at home 1.21 0.91 to 1.60 0.187 1.25 0.74 to 2.11 0.400 
Nursing home resident 1.63 1.24 to 2.15 <0.001 0.61 0.34 to 1.12 0.114 
 
*Calculated as number of comorbidities from the following list: IHD, cardiac 
failure, stroke/neurological disease, significant pulmonary disease and diabetes.  
 
Table 4: Factors associated with dying with disease control and treatment failure 
identified using competing risks regression with backwards selection. 
 
 Event = Death with disease controlled Event =Treatment failure 
 SHR 95% CI p-value SHR 95% CI p-value 
Age 1.03 1.01 t0 1.05 0.003 0.96 0.94 to 0.98 0.001 
Tumour size    1.03 1.00 to 1.05 0.025 
TPM grade    3.52 1.90 to 6.50 <0.001 
Axilla involvement    2.01 1.09 to 3.73 0.026 
Co-morbidities*       
   0 1  0.009    
   1 to 2 1.27 0.89 to 1.80     
   3 or more 1.95 1.27 to 3.00     
Impaired mobility 1.31 0.95 to 1.83 0.102    
*Calculated as number of comorbidities from the following list: IHD, cardiac 
failure, stroke/neurological disease, significant pulmonary disease and 
diabetes.  
 
Table 5: Summary of type and time to treatment failure.  
 N(%) Time to event, 
Mean (sd) 
Median (IQR) 
Total failures/ time to first failure 63 30.3 (20.2) 
28 (14 to 41) 
Required radiotherapy 18 (28.6) 26.5 (19.1) 
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20.5 (13 to 34) 
Required surgery 26 (41.3) 29.7 (20.5) 
25.5 (10 to 51) 
Died with uncontrolled disease 32 (50.8) 37.3 (23.0) 
33 (22 to 44) 
Died of breast cancer 22 (34.9) 44.0 (22.3) 
35 (30 to 51) 
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STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 
Item 
No. Recommendation 
Page  
No. 
Relevant text from manuscript 
Title and 
abstract 
1 (a) Indicate the study’s 
design with a commonly 
used term in the title or the 
abstract 
1, 6 An observational study investigating failure of primary endocrine therapy for operable breast cancer in the 
elderly 
 
(b) Provide in the abstract 
an informative and balanced 
summary of what was done 
and what was found 
6  
A retrospective observational study was performed on consecutive patients with ER positive early stage 
breast cancer treated with PET between 2005 and 2015 in the three breast units in the north east of 
England.  The primary outcome measure was treatment failure and secondary outcome measure was 
disease progression.  
 
 
488 patients were included with mean follow up 31 months (SD 23).  Overall, 206 patients were still alive 
with their disease controlled at the end of follow up, 219 had died with their disease controlled and 63 
(12%) experienced treatment failure.  Younger age [SHR 0.96 (95% CI 0.94 to 0.99) p 0.013], larger 
tumours [SHR 1.03 (1.01 to 1.06) p 0.015], grade 3 cancers [SHR 3.58 (1.93 to 6.63) p<0.001] and axillary 
lymph node metastases [SHR 1.93 (1.06 to 3.52) p 0.030] were all independent predictors of treatment 
failure. Disease progression was reported in 86 (17.6%) of patients. 
 
Introduction  
Backgroun
d/rationale 
2 Explain the scientific 
background and rationale 
for the investigation being 
reported 
8,9 Frailty and the burden of co-morbid disease increase with advancing age[1], as does the incidence of breast 
cancer[2].  Whilst surgery is the standard initial treatment of choice for early breast cancer[3], some 
elderly and frail patients with oestrogen receptor (ER) positive cancers  who are considered too unfit for 
general anaesthesia, may be given primary endocrine therapy (PET)[4,5].   PET has been shown to be 
effective in treating breast cancer[6].  
 
PET use has become widespread. In 2012 a UK-based questionnaire study reported that 93% of surgeons 
advocated the use of PET in early operable breast cancer in the elderly[7].  Whilst PET provides relatively 
good local control in the short term (2-3 years), it has been found to be inferior to surgery long-term.  This 
was shown in a Cochrane meta-analysis that showed no difference in overall survival between PET and 
surgery, but an inferiority of PET in local disease control[8]. However, all but one study included were 
unselected for oestrogen receptor (ER) status, and all used Tamoxifen which has now largely been 
superseded by Aromatase inhibitors (AIs)[9].  
 
The International Society of Geriatric Oncology (SIOG) advise that PET may be considered in patients with 
a short life expectancy (<2 years) or unfit for surgery[10]. Frequently, clinician’s decision making in 
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allocating PET is subjective, made in a busy time-pressured outpatient clinic, with little objectivity. NHS 
time- targets may also influence clinician’s decision making[11], as formal anaesthetic or geriatric opinions 
can take time.  
 
Treatment failure on PET is potentially catastrophic for the patient. As such, patient selection is key.   
Difficulties in patient selection are compounded by an increasing life expectancy, with patients with 
multiple co-morbidities able to live longer due to improvements in geriatric and medical care[12-14]. 
Objectives 3 State specific objectives, 
including any prespecified 
hypotheses 
9 Few studies have directly sought to analyse failure of PET.   The aim of this study was to determine the 
failure rate of PET in the North East of England, and to identify predictors of failure.   
 
Methods  
Study 
design 
4 Present key elements of 
study design early in the 
paper 
9,10 An observational study was performed on patients with ER positive early breast cancer treated with PET 
between January 2005 and December 2015.  Data collection was performed retrospectively and subjects 
were identified from the three North East of England breast-screening units.   Local breast cancer multi-
disciplinary team databases were used to select patients.  Patients were excluded if they had inoperable or 
metastatic disease at presentation, or if endocrine therapy was given as neo-adjuvant treatment to 
downstage the tumour prior to surgery.  
 
Setting 5 Describe the setting, 
locations, and relevant 
dates, including periods of 
recruitment, exposure, 
follow-up, and data 
collection 
9-11 As above 
Participant
s 
6 (a) Cohort study—Give the 
eligibility criteria, and the 
sources and methods of 
selection of participants. 
Describe methods of follow-
up 
Case-control study—Give the 
eligibility criteria, and the 
sources and methods of case 
ascertainment and control 
selection. Give the rationale 
for the choice of cases and 
controls 
Cross-sectional study—Give 
the eligibility criteria, and 
the sources and methods of 
9 Length of follow up was determined by case note review. The date of diagnosis was taken from when the 
diagnosing histology was made available. Patients were ultimately followed up until they died, or were still 
under follow up at the censor point (December 2015). Cause of death was either determined from the case 
notes or from the patient’s general practitioner.  
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selection of participants 
(b) Cohort study—For 
matched studies, give 
matching criteria and 
number of exposed and 
unexposed 
Case-control study—For 
matched studies, give 
matching criteria and the 
number of controls per case 
  
Variables 7 Clearly define all outcomes, 
exposures, predictors, 
potential confounders, and 
effect modifiers. Give 
diagnostic criteria, if 
applicable 
9-11 The primary outcome measure was treatment failure. This was defined as patients either dying with 
uncontrolled local disease; patients dying of metastatic breast cancer (where there was only local disease 
on presentation), or patients requiring surgery or radiotherapy to control local progression. Time to failure 
was recorded either from diagnosis to death, or diagnosis to surgery or radiotherapy.  Treatment was 
considered a success if the patient died of causes unrelated to their breast cancer and their disease was 
under control at that point, or if they were still alive at the time of censoring with their disease controlled.  
The secondary outcome measure was disease progression. This was defined as an increase in size of 
tumour whilst on PET. Time to progression was recorded from diagnosis to when the tumour clinically or 
radiologically increased in size.  
 
Data 
sources/ 
measureme
nt 
8*  For each variable of 
interest, give sources of data 
and details of methods of 
assessment (measurement). 
Describe comparability of 
assessment methods if there 
is more than one group 
9-11 Data collection was performed retrospectively and subjects were identified from the three North East of 
England breast-screening units.   Local breast cancer multi-disciplinary team databases were used to select 
patients.  Patients were excluded if they had inoperable or metastatic disease at presentation, or if 
endocrine therapy was given as neo-adjuvant treatment to downstage the tumour prior to surgery.  
 
Tumour characteristics 
Pathological information was based on needle-core biopsies on first presentation.  Strength of ER status 
was determined by the histochemical ‘quickscore’ (value out of eight)[15]. HER-2 positivity was defined by 
immunohistochemistry or fluorescent in-situ hybridization (FISH) in borderline cases[16]. The grade of the 
tumour was catergorised 1-3 by the modified Scarf-Bloom-Richardson (SBR) criteria[17].  Lymph node 
involvement was recorded either from histology or cytology, and in some cases based purely on ultrasound 
appearances if a tissue-sample was not acquired. Tumour size was based on the maximum dimensions 
from ultrasound.  
 
Treatment decisions and patient characteristics 
Patients were seen for diagnosis and treatment planning in the outpatient clinic, with support from the 
local Multidisciplinary team (MDT). Case notes and outpatient clinic letters were reviewed to determine 
the first choice of endocrine agent.  Data on patient co-morbid disease, cognition and social circumstances 
was also collected.   Consultation by geriatricians or anaesthetists was recorded.  The use of predictive 
indexes which facilitate decision making were recorded, as was any additional information on other 
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surgeries unrelated to their breast cancer following diagnosis.  
 
Bias 9 Describe any efforts to 
address potential sources of 
bias 
  
Study size 10 Explain how the study size 
was arrived at 
9  
Continued on next page   
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Quantitative 
variables 
11 Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen 
and why 
  
Statistical 
methods 
12 (a) Describe all statistical methods, 
including those used to control for 
confounding 
11 Patients still alive without treatment failure were censored at end of follow-up at end of 
December 2015.  Characteristics in the three groups (treatment failures, patient who died 
with controlled disease and patients still alive with controlled disease) were compared using 
the Kruskal Wallis test, Chi-square test or Fisher’s exact test, as appropriate. Where patients 
had bilateral disease, tumour size and characteristics were summarised using data from the 
largest or most advanced tumour.  
The cumulative risk of death with controlled disease and risk of treatment failure was 
calculated with the alternate outcome treated as a competing risk. Competing risks regression 
models were used to identify factors associated with dying with controlled disease and with 
treatment failure.  Results are presented as sub-hazard ratios (SHR) with 95% confidence 
intervals (CI).  
 
(b) Describe any methods used to 
examine subgroups and interactions 
11 As above 
(c) Explain how missing data were 
addressed 
  
(d) Cohort study—If applicable, explain 
how loss to follow-up was addressed 
Case-control study—If applicable, 
explain how matching of cases and 
controls was addressed 
Cross-sectional study—If applicable, 
describe analytical methods taking 
account of sampling strategy 
  
(e) Describe any sensitivity analyses   
Results 
Participants 13* (a) Report numbers of individuals at 
each stage of study—eg numbers 
potentially eligible, examined for 
eligibility, confirmed eligible, included in 
the study, completing follow-up, and 
analysed 
12  
(b) Give reasons for non-participation at 
each stage 
  
(c) Consider use of a flow diagram   
Descriptive data 14* (a) Give characteristics of study 13 See table 1 
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participants (eg demographic, clinical, 
social) and information on exposures 
and potential confounders 
(b) Indicate number of participants with 
missing data for each variable of interest 
13 As above 
(c) Cohort study—Summarise follow-up 
time (eg, average and total amount) 
12 Data were included from 488 patients who were followed for a total of 1271 person years. 
Among all patients the mean follow up was 31.3 (standard deviation = 23.0) months with a 
median of 28 months (Interquartile range = 5 to 41). Among 232 patients who died mean 
follow up was 27.4 (24.0) months and median 21 (10 to 36 months). The remaining 255 
patients were alive at the end of December 2015 by which time they had provided a mean 
follow up of 35.5 (21.1) months and median of 32 (21 to 45) months.   
Outcome data 15* Cohort study—Report numbers of 
outcome events or summary measures 
over time 
12-
14 
Overall, 206 patients were still alive with their disease controlled at the end of follow up, 219 
had died with their disease controlled and 63 experienced treatment failure.  
Case-control study—Report numbers in 
each exposure category, or summary 
measures of exposure 
  
Cross-sectional study—Report numbers 
of outcome events or summary 
measures 
  
Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted 
estimates and their precision (eg, 95% 
confidence interval). Make clear which 
confounders were adjusted for and why 
they were included 
12-
15 
See tables 2-5 and Figure 1 
(b) Report category boundaries when 
continuous variables were categorized 
  
(c) If relevant, consider translating 
estimates of relative risk into absolute 
risk for a meaningful time period 
  
Continued on next page   
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Other analyses 17 Report other analyses done—eg analyses 
of subgroups and interactions, and 
sensitivity analyses 
  
Discussion 
Key results 18 Summarise key results with reference to 
study objectives 
18 Advanced age and a higher burden of co-morbid disease are associated with dying with 
controlled disease. Younger patients, who tend to live longer, are more likely to experience 
treatment failure. Younger patients with higher histological grade, larger tumours and 
axillary lymph node metastases are most at risk of treatment failure.   
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
20-21 However, there are limitations.  The majority of the information gained was reliant on case 
records, in particular treatment decisions, documentation of co-morbidities, living 
arrangements and mobility. There was a large degree of heterogeneity in how 
comprehensive clinic letters were. To account for this, nursing notes, routinely filed in the 
case records were also examined. Surveillance of tumours was also variable. Some patients 
would purely have clinical follow up where clinical examination would assess for disease 
control, whereas others would use mammography and ultrasound.  Much of these problems 
are the result of a retrospective study design, and involving breast units from three 
independent NHS trusts.   There is a positive however of a multi-institution study as it 
reflects wider practice and natural variations between units. This in turn makes the results 
more generalisable to other breast units.  
 
Interpretation 20 Give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from 
similar studies, and other relevant 
evidence 
19-22 This series has identified key factors associated with treatment failure on PET. Younger 
patients, with larger high-grade tumours and axillary node metastases would benefit from 
surgery over primary endocrine therapy.  Patients with limited life expectancy, can be 
treated with PET as it likely they will die from non-breast cancer related causes.  Treatment 
decision making in elderly patients in routine clinical practice is a challenge, particularly as 
not all patients fall into two distinct groups as described above.  There is evidence from this 
series that some patients living beyond three years can maintain disease control longer-
term, and as such adds to the difficulty in accurately advising patients as to the most 
appropriate treatment.  Surgery has been shown to be safe with regional anaesthesia[42], 
allowing increasingly frail patients greater access to surgery, and as such should be the 
standard of care for operable breast cancer. PET with AIs in post-menopausal women may 
be a viable long-term alternative in the right circumstance and in the absence of failure risk 
factors.  A specific prognostic index to identify the likelihood of treatment failure would give 
more objectivity in treatment planning, allowing the clinician to counsel the patient 
appropriately. However, no such model is yet widely available.   
 
Generalisability 21 Discuss the generalisability (external 
validity) of the study results 
21  
Other information  
 36 
Funding 22 Give the source of funding and the role of 
the funders for the present study and, if 
applicable, for the original study on which 
the present article is based 
4  
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
 
 
 
